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Summary  24 
Population Pharmacokinetic (PK)-Pharmacodynamic (PD) (PKPD) models are increasingly used in drug 25 
development and in academic research. Hence designing efficient studies is an important task. 26 
Following the first theoretical work on optimal design for nonlinear mixed effect models, this 27 
research theme has grown rapidly. There are now several different software tools that implement an 28 
evaluation of the Fisher information matrix for population PKPD. We compared and evaluated five 29 
software tools: PFIM, PkStaMP, PopDes, PopED, and POPT. The comparisons were performed using 30 
two models: i) a simple one compartment warfarin PK model; ii) a more complex PKPD model for 31 
Pegylated-interferon (peg-interferon) with both concentration and response of viral load of hepatitis 32 
C virus (HCV) data. The results of the software were compared in terms of the standard error values 33 
of the parameters (SE) predicted from the software and the empirical SE values obtained via 34 
replicated clinical trial simulation and estimation. For the warfarin PK model and the peg-interferon 35 
PKPD model all software gave similar results. Of interest it was seen, for all software, that the simpler 36 
approximation to the Fisher information matrix, using the block diagonal matrix, provided predicted 37 
SE values that were closer to the empirical SE values than when the more complicated approximation 38 
was used (the full matrix). For most PKPD models, using any of the available software tools will 39 
provide meaningful results, avoiding cumbersome simulation and allowing design optimisation. 40 
  41 
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Introduction  42 
Estimation of pharmacokinetic (PK) parameters for an individual using nonlinear regression 43 
techniques started in the 1960’s, followed by estimation of dose-response and of pharmacodynamics 44 
(PD) models. At around the same time mathematical approaches to defining the problem of optimal 45 
design for parameter estimation in nonlinear regression was addressed (1-3). However this did not 46 
reach the PK literature until some 20 years later (4). The problem was not only to draw inference 47 
from data but also to define the best design(s) for estimation of parameters using maximum 48 
likelihood or other estimation methods.  For this purpose, the Fisher Information matrix (FIM) was 49 
used to describe the informativeness of a design, i.e.  how much information the design has in 50 
relation to parameter estimation. Typically in PK the FIM is summarized by its determinant and 51 
maximising the determinant, termed D-optimality, is equivalent to minimising the asymptotic 52 
confidence region of the parameters, i.e. getting the most precise parameter estimates (5-9). 53 
However, beyond theoretical developments, a limitation of individualised optimised designs of PKPD 54 
studies is that those designs do not acknowledge population information and hence cannot have 55 
fewer sampling times per individual than parameters to estimate. In addition, optimal designs with a 56 
large number of observations per patient will have replicated optimal sampling times; which were 57 
not favoured by pharmacologists interested in exploring complex PK models.  Some later work also 58 
explored Bayesian designs, where a priori distributions of the parameters were considered, and 59 
individual parameters were estimated using maximum a posteriori probability (MAP). Optimal 60 
designs for MAP estimation optimise individual designs given prior population information and are 61 
suitable for e.g. therapeutic drug monitoring designs (10, 11). Since 1985, the software Adapt 62 
(https://bmsr.usc.edu/software/adapt/) has included methods for optimal design in nonlinear 63 
regression using several criteria for MAP estimation.  64 
The population approach was introduced by Sheiner et al. (12) for PK analyses in the late 1970’s and 65 
since the 1980’s there has been a large increase in the use of this approach as well as extensions to 66 
PKPD. Estimation was mainly based on maximum likelihood using nonlinear mixed effects models 67 
(NLMEM) thanks to the software NONMEM. To our knowledge the first article studying the impact of 68 
a ‘population design’ on properties of estimates was performed in early 1990’s by Al Banna et al. (13) 69 
for a population PK and a population PKPD example. In this work the author used clinical trial 70 
simulation (CTS) to explore possible designs. The authors studied the influence of the balance of 71 
number of patients, number of sampling times and locations of the sampling times on the precision 72 
of the parameter estimates. Several papers, all using CTS, were published (14-16) showing that some 73 
designs could be rather poor, and that very sparse designs also performed poorly. The FDA’s 74 
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Guidance for Industry Population Pharmacokinetics (17) from 1999 includes a specific section on 75 
design, and suggests that simulation, based on preliminary information, should be performed to 76 
“anticipate certain fatal study designs, and to recognize informative ones”.  77 
Using CTS for design evaluation requires a large number of data sets to be simulated and then fitted 78 
under each proposed design which is computationally expensive. However, since CTS is a user driven, 79 
heuristic approach, then it can miss important regions of the design space because only a fixed 80 
number of designs are investigated. Subsequently it was suggested to use the FIM in NLMEM to 81 
predict asymptotic standard errors (SE) and define optimal designs without the need for intensive 82 
simulations. Because the population likelihood has no closed-form expression the proposed 83 
approach for defining the population FIM was to use a first-order linearisation of the model around 84 
the random effects (which is the same as used for the first-order (FO) estimation methods). This 85 
approximation results in a mixed effect model where the random effects enter the model linearly 86 
(rather than nonlinearly) and hence has properties that are similar to linear mixed effects model. The 87 
expression for the population FIM was first published in Biometrika in 1997 (18). In this work the FIM 88 
was derived for a population PK example and an algorithm was proposed to optimise designs based 89 
on the population FIM. This paper launched the new field of optimal design for nonlinear mixed 90 
effects models. It has been quoted in the section ‘other influential papers of the 1990’s’ in a review 91 
in Biometrika (19).  92 
Since 1997 several methodological papers from various academic teams have published different 93 
extensions, for instance robust designs, sampling windows, compound designs, multiple response 94 
models, methods for discrete longitudinal data, and other approximations of the FIM, etc.   Most 95 
importantly, the derivation of the expression of the FIM was implemented in several software tools, 96 
the first one PFIM (20) in 2001 appeared simultaneously in both R (http://www.r-project.org/)  and 97 
Matlab (http://www.mathworks.fr/products/matlab/). This was followed by POPT (21), and later to 98 
incorporate an interface version WinPOPT, PopED (22), PopDes (23) and PkStaMp (24). There are 99 
now five different software tools, all implementing the first-order approximation, with some tools 100 
implementing one or several other approximations. These tools for designing population PKPD 101 
studies are gaining popularity. In a recent study performed among European Federation of 102 
Pharmaceutical Industries and Associations members’ (25), it was found that 9 out of 10 103 
pharmaceutical companies are using one of these software tools for design evaluation or 104 
optimisation, mainly in phases I and II.  105 
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The computation of the FIM is complex and depends on the numerical implementation. The purpose 106 
of the present work was therefore to compare the results provided by those different software tools 107 
in terms of FIM and predicted SE values. The same basic approximations were used in each software, 108 
and the comparison was performed for two examples: (1) a simple PK example described by a one-109 
compartment model with first-order absorption and linear elimination  and (2) a more complex PKPD 110 
example where the PD component is defined by a system of nonlinear ordinary differential equations 111 
(ODE).  The objective was to explore the results from different software tools and to compare results 112 
against those obtained using CTS. We wanted to show the user community that similar results would 113 
be obtained with any software tool although programmed in different languages and by different 114 
authors. This was also studied in the case of a multiple responses ODE model where the numerical 115 
imbrication between ODE solver and numerical differentiation is complex.  The results were provided 116 
by the software developers, all authors of this article, who were given the equations of the models, 117 
the values of the parameters and the designs to be evaluated. Results were compared to those 118 
obtained by CTS.   119 
The article is organized as follows: first the description of the population FIM for NLMEM, second a 120 
description of the various software tools, and then an evaluation of the two examples. As no design 121 
optimisation was performed in the present study, no optimisation characteristics or algorithms are 122 
described. 123 
 124 
Statistical methods for design in NLMEM 125 
A design for a multi-response NLMEM is composed of N subjects each with an associated 126 
elementary design iξ ( 1,...,i N= ). Hence a design for a population of N subjects can be described 127 
as 128 
 ( )1,..., Nξ ξΞ =  (1) 129 
Each elementary design iξ  can be further divided into sub-designs  130 
( )1, ,i i iKξ ξ ξ= …                 (2) 131 
with ikξ , 1,...,k K=  being the design associated with the kth response.  (e.g. drug concentration, 132 
metabolite concentration, effect). It may thus be possible to have all responses measured at different 133 
times, termed an unbalanced design.  134 
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A design for subject i at a response 1,...,k K= often consists of several design variables which might 135 
be constant between observations, e.g. the drug dose, or vary between observations, e.g. the times 136 
at which the response variable is measured. 137 
An elementary design lξ  can be the same within a group l  of lN subjects ( 1, ,l L= … ). Using a 138 
similar notation for the complete population design Ξ  in a limited number of L  groups of different 139 
elementary designs gives:  140 
 [ ] [ ]( )1 1, ,..., ,L LN Nξ ξΞ =  (3) 141 
where the total number of subjects in the design, N , is equal to the sum of the subjects in the L  142 
elementary designs. At the extreme, each subject may have a different design, L = N, or each subject 143 
may have the same design, L = 1. 144 
In a NLMEM framework with multiple response, the vector of observations iY  for the i
th
 subject is 145 
defined as the vector of K different responses:  146 
        1 1, , ,
TT T T
i i i iKY y y y =  …                (4) 147 
where iky , 1, ,k K= …  is the vector of nik observations for subject i and response k  modelled as 148 
 ( ) ( )f , h , ,ik k i ik k i ik iky θ ξ θ ξ ε= +  (5) 149 
where fk(.) is the structural model for the k
th
 response, iθ  is the ith subject’s parameter vector, hk(.) is 150 
the residual error model for response k, often additive (h= ikε ), proportional (h= ( )fk ikε⋅ ) or a 151 
combination of both, ikε  is the residual error vector for response k in subject i. In this paper additive 152 
(homoscedastic) or proportional (heteroscedastic) error models will be used in the examples so that 153 
only one residual variance parameter is defined for each response.  To simplify notation we assume 154 
that ikε are normally distributed and independent between responses (which is not necessary, see 155 
e.g. (26, 27)) with mean zero and variance Σk=diag( 2kσ ). The individual parameter vector iθ , with 156 
parameter(s) that might be shared between responses, is described as 157 
 ( )g ,i ibθ β=  (6) 158 
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where β  is the u-vector of  fixed effects parameters, or typical subject parameter and bi, the vector 159 
of the v  random effects for the subject i defining the subject deviation from the typical value of the 160 
parameter. We  assume that bi is normally distributed with a mean of zero and a covariance matrix 161 
Ω  of size  × . Again, to simplify notation we assume a diagonal (which is not necessary, see e.g. 162 
(18, 27-29)) interindividual covariance matrix ( Ω ) with diagonal elements ( 2 21 ,..., vω ω ). The vector of 163 
population parameters is thus defined as 164 
 [ ] 2 2 2 21 1, , ,..., , ,...,v Kψ β λ β ω ω σ σ = =    (7) 165 
where 
2 2 2 2
1 1,..., , ,...,v Kλ ω ω σ σ =    is the vector of all variance components. 166 
The population Fisher information matrix ( ),FIM ψ Ξ  for multiple response models with the 167 
population design Ξ  is given by:  168 
( ) ( )
2
,
, T
L Y
FIM E
ψψ
ψ ψ
 ∂
Ξ = −  ∂ ∂ 
                                                                                   (8) 169 
where ( ),L Yψ  is the log-likelihood of all the observations Y given  the population parameters ψ .  170 
Assuming independence across subjects, the log-likelihood can be defined as the sum of the 171 
individual contribution to the log-likelihood: ( ) ( )
1
, ,
N
i
i
L Y L Yψ ψ
=
= ∑ . Therefore, the population 172 
Fisher information matrix (calculated using the second derivative of the log-likelihood) for N subjects 173 
can also be defined as the sum of the N elementary information matrices ( ), iFIM ψ ξ  computed for 174 
each subject i: 175 
( ) ( )
1
, ,
N
i
i
FIM FIMψ ψ ξ
=
Ξ = ∑                                                                                              (9) 176 
In the case of a limited number of L groups (where each individual in a group share the same design), 177 
as in Equation (3), the population FIM is expressed by:  178 
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  ( ) ( )
1
, ,
L
l l
l
FIM N FIMψ ψ ξ
=
Ξ = ∑                                                                    (10)179 
  180 
For one subject, given the design variables iξ and the NLMEM model, the FIM is a block matrix 181 
defined as: 182 
 ( )
1FIM ,
2i
A C
C B
ψ ξ
 
 =
 
 
 (11) 183 
where ( ) 1,
2i
FIM Aβ ξ = is the block of the Fisher matrix for the fixed effects β  and  184 
( ) 1,
2i
FIM Bλ ξ =  is the block of the Fisher matrix for the variance components λ . 185 
When a standard FO approximation of the model is performed (see appendix), then the distribution 186 
of the observations in patient i with design ξi is approximated by ( )~ N ,i i iY E V . Expressions for the 187 
population mean iE and population variance iV  are given in the appendix. Then the following 188 
expression for blocks A, B and C are obtained (18, 30, 31), ignoring indices i for simplicity : 189 
1 1 12 tr
T
pq
p q p q
E E V VA V V Vβ β β β
− − −
 ∂ ∂ ∂ ∂
≅ +   ∂ ∂ ∂ ∂ 
 with ( ), 1..dimp q β=
 
190 
1 1
pq
p q
V VB V Vλ λ
− −
∂ ∂
≅
∂ ∂    with ( ), 1..dimp q λ=  (12) 191 
1 1trpq
p q
V VC V Vλ β
− −
 ∂ ∂
≅   ∂ ∂ 
 with ( ) ( )1..dim , 1..dimp qλ β= =   192 
 193 
This expression of the FIM (eq. 12) will be referred to as the full FIM in this paper.  194 
If the approximated variance V is assumed independent of the typical population parameters β , the 195 
matrix C will be zero and the matrices A and B will instead be defined as: 196 
 
12
T
pq
p q
E EA Vβ β
−
∂ ∂
≅
∂ ∂
     with ( ), 1..dimp q β=           (13) 197 
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1 1
pq
p q
V VB V Vλ λ
− −
∂ ∂
≅
∂ ∂    with ( ), 1..dimp q λ=    198 
  199 
which will be termed the block diagonal FIM in the following. The explicit formula for ( ), iFIM β ξ  200 
using the block diagonal form is given in the appendix. More information about the derivation of the 201 
FIM or other approximations are reported in (27, 28, 30, 32-34). 202 
 203 
Software description 204 
There are presently five software tools that implement experimental design evaluation and 205 
optimisation of the FIM for multiple response population models. The five software tools are (in 206 
alphabetical order) : PFIM (35), PkStaMp (24), PopDes (23), PopED (27, 31) and POPT (21). Four of 207 
them have been developed by academic teams.  208 
PFIM (Population Fisher Information Matrix) is the only tool that is using the software R, the other 209 
software packages have been developed under the numerical computing environment MATLAB. The 210 
first version of PFIM appeared in 2001 and since this date several releases have been issued. It is 211 
available at www.pfim.biostat.fr.  A graphical user interface (GUI) package using the R software 212 
(PFIM Interface) is also available but does not include recent methodological developments. 213 
Pk StaMP (Pharmacokinetic Sampling Times Allocation – Matlab Platform) is a library compiled as a 214 
single executable file which does not require a MATLAB license. The developers can share the stand-215 
alone version with anyone interested. PopDes (Population Design) has been developed at the 216 
University of Manchester and this application software is available at www.capkr.man.ac.uk/home 217 
since 2007.  PopED (Population optimal Experimental Design), freely available at poped.sf.net, 218 
consists of two parts, a script version, responsible for all optimal design calculations, and a GUI. The 219 
script version can use either MATLAB or Freemat  (http://www.freemat.sf.net)(a free alternative to 220 
MATLAB) as an underlying engine. Some advanced PopED features such as automatic and symbolic 221 
differentiation, Laplace approximation of Bayesian criteria and mode base linearisation are not 222 
available in FreeMat, however all features presented in Table 1 are available in PopED using either 223 
FreeMat or Matlab. POPT (Population OPTimal design) was developed from PFIM (MATLAB) in 2001 224 
and is constructed as a set of MATLAB scripts. POPT requires MATLAB and can run on FreeMat. This 225 
tool can be downloaded on the website www.winpopt.com. All the software tools run on any 226 
common operating system platform (e.g. Windows, Linux, Mac).  227 
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 228 
Comparison of software for design evaluation  229 
As we focus on design evaluation and not design optimisation, we first compared the software tools 230 
with respect to a) required programming language, b) availability, c) library of PK and PD models, and 231 
ability to deal with:  d) multiple response models, e) models defined by differential equations, e) 232 
unbalanced multiple response designs, f) correlations between random effects and/or residuals, g) 233 
models including inter-occasion variability, h)  models including fixed effects for the influence of 234 
discrete covariates on the parameters,  i)  computation of the predicted power. Table 1 is a summary 235 
of the comparison of the software with respect to these different aspects.  Globally, for all software 236 
tools, the library of PK models includes one, two and three compartment models, with bolus, 237 
infusion and first-order (e.g. oral) administration, after a single dose, multiple doses and at steady 238 
state. PK models with first-order elimination and models Michaelis-Menten elimination are available. 239 
Regarding PD models, immediate linear and Emax models and turnover response models are 240 
available. 241 
Over recent years, those tools have included various improvements in terms of model specification 242 
and calculations of the FIM. For all of them, design evaluation can be performed for single or multiple 243 
response models either using libraries of standard PK and PD models or using a user-defined model. 244 
For the latter, regardless of the software used, the model can be written using an analytical form or 245 
using a differential equation system. In the case of multiple response models, population designs can 246 
be different across the responses for all the software. Regarding the calculations of the information 247 
matrix, the majority of the software can handle either a block diagonal Fisher information matrix 248 
(block FIM) or the full matrix (full FIM). Otherwise, only PopDes and PopED allow for calculations for 249 
a model with both correlation between random effects (full covariance matrix Ω) and correlation 250 
between residuals (full covariance matrix Σ), PKStamp allows full covariance matrix Ω. It is possible in 251 
PFIM, PopDes and PopED to use models with inter-occasion variability (IOV) and models including 252 
fixed effects for the influence of discrete covariates on the parameters. The computation of the 253 
predicted power of the Wald test (30, 36) for a given distribution of a discrete covariate can be 254 
evaluated in PFIM, PopDES and PopED frameworks.   255 
 256 
 257 
 258 
 259 
 260 
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Examples 261 
Two different examples were used to illustrate the performance of the five population design 262 
software tools. Note that the examples evaluated the prediction for a given design, by evaluating the 263 
FIM and the predicted asymptotic SEs, without design optimisation. This was done to evaluate the 264 
core calculations of the FIM. The FIM is evaluated with the full and the block diagonal derivation (eq. 265 
12, 13) with the different software tools. 266 
In the first example a one compartment PK model (based on a warfarin PK model) with first-order 267 
absorption was used (35). The design of that study consisted of 32 subjects with a single dose of 70 268 
mg (a dose of 1mg/kg and a weight of 70 kg), and with 8 sampling times post-dose (in hours): 269 
[ ]( ) ( )1 1 1, ,32Nξ ξΞ = =          270 
( ) ( )1 0.5,1,2,6,24,36,72,120itξ = =  271 
The residual error model was proportional (h = f ε⋅ ) with a coefficient of variation of 10% (272 
2 0.01σ = ) and exponential random effects were assumed for all parameters ( g ibeβ= ). Table 2 273 
reports the model parameters and their values. The dose and design are based on (34, 37). 274 
For the second example a multiple response PKPD model with repeated dosing was selected with the 275 
same design across responses (38).  The model describes hepatitis C virus (HCV) kinetics, or more 276 
specifically, the effect of peg-interferon dose of 180 μg/week administered as a 24 hour infusion 277 
once a week for 4 weeks. The same sequence of 12 sampling times for both PK and PD 278 
measurements (in days, post-first-dose) was used for 30 subjects: 279 
{ }( ) ( ), , , ,30PK PD PKPD PK PDNξ ξ ξ ξ Ξ = =        280 
 ( ) ( )0,0.25,0.5,1,2,3,4,7,10,14,21,28PK PD itξ ξ= = =  281 
The HCV model is described by the following system of ODEs: 282 
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( ) ( ) ( )
( ) ( ) ( )
( ) ( )( ) ( )
( ) ( ) ( )
,                                  0 0                 
,                                 0 0
,                          0
,                   
a
a e
dX k X t r t X
dt
dA k X t k A t A
dt
dT c
s T t eW t d T
dt pe
dI
eW t T t I t
dt
δ
δ
= − + =
= − =
= − + =
= − ( )
( ) ( ) ( ) ( )
50
          0
1 ,    0( )
n
n n
sep dcI
p e
C tdW sep dcp I t cW t W
dt C t EC c e
δ
δ
δ
δ
−
=
 
−
 = − − =
 + 
   283 
   284 
 where ( ) ( ) dC t A t V=  is the drug concentration at time t and r(t) is the constant infusion rate. The 285 
viral dynamics model considers target cells, T, productively infected cells, I and viral particles, W. 286 
Target cells are produced at a rate s and die at a rate d. Cells become infected with de-novo infection 287 
rate e. After infection, these cells are lost with rate δ. In the absence of treatment, virus is produced 288 
by infected cells at a rate p and cleared at a rate c, for more details see (38, 39). The model for each 289 
response in subject i  is defined as 290 
( )
( ) ( )( )
,
10 , 10log log
i PK i iPK
i PD i iPD
y C t
y W t
ε
ε
= +
= +
    291 
An additive error model was assumed for both PK and PD (log viral load) compartments from which 292 
observations were drawn with a standard deviation of 0.2. Some of the parameters in the model are 293 
fixed (p, d, e, s). For the other seven parameters (ka, ke, Vd, EC50, n, δ, c), log transformation was 294 
made with additive random effects on the log fixed effect with a variance ω
2
 of 0.25. All parameters 295 
and their values are listed in Table 3.  296 
 297 
Methods 298 
 299 
For each example using each software tool, we computed the FIM based on the FO linearisation, 300 
given the parameters and the design. We used both the block-diagonal and the full FIM (not available 301 
in POPT). From the FIM, we computed the predicted SE values for each parameter and the 302 
13 
 
 
 
information D-criterion which is defined as the determinant of the FIM to the power of one over the 303 
number of parameters: 
( )1/dimFIM ψ  . 304 
To investigate the FIM predictive performance, the empirical SE values were also estimated using 305 
CTS. More precisely, for each example, multiple data sets were simulated and then fitted using the 306 
Stochastic Approximation Expectation Maximisation (SAEM) algorithm in MONOLIX 2.4 307 
(www.lixoft.eu) and, for the PK example also with the FOCEI algorithm in NONMEM 7 308 
(http://www.iconplc.com/technology/products/nonmem/).  Empirical standard errors were derived 309 
from the estimated parameters. The empirical D-criterion was computed from the normalized 310 
empirical variance-covariance matrix of all estimated parameters, ( ) ( )1/dim1cov ψψ − .  Because the 311 
CTS was much more time consuming for the HCV PKPD model, we did not perform the estimation 312 
with NONMEM and we did only 500 replicates, whereas we simulated 1000 replicates for the 313 
warfarin PK model. 314 
For the CTS, to compute the empirical covariance matrix, the full variance-covariance matrix of all the 315 
estimated vectors was computed, not as two separate blocks for fixed effects and random 316 
components.  317 
 318 
Results 319 
 320 
For the PK model, the results show no differences between the optimal design software tools when 321 
evaluating the FIM using the block diagonal and full form. In the same way, all software reported the 322 
same expected D-criterion (Figure 1), and the same expected relative standard errors (RSE) values 323 
expressed in % (Table 4).   324 
In this example, the block diagonal FIM calculations gave an expected D-criterion that was very 325 
similar to the observed D-criterion based on the inverse of the empirical covariance matrix (Figure 1).  326 
However, for all software, the block diagonal D-criterion is slightly smaller than the NONMEM FOCEI 327 
based criterion. Note that the result from MONOLIX is lower than the expected D-criterions, in line 328 
with theoretical expectations the Cramer-Rao inequality (FIM is an asymptotic upper bound on the 329 
information). The full FIM predicts considerably more information compared to the simulations 330 
(expected D-criterions are larger than the observed values), and predicts total information that is 331 
farther from the empirical values than the block diagonal calculations. The same trends are evident 332 
when looking at the RSE values, reported in Table 4. Good agreement between the CTS and the block 333 
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diagonal FIM was found, while the full FIM predicted considerably higher precision in Kaβ  and βCL/F334 
. 335 
For the more complicated PKPD model, results are summarized In Figure 2 and Table 5 where RSE (%) 336 
are reported. The D-criterion reveals negligible differences between any of the software (Figure 2) 337 
and also almost no difference between predicted SE values (Table 5). In this example, as in the PK 338 
example, using the block diagonal FIM gave D-criterion predicted values that were very similar to the 339 
D-criterion based on the inverse of the empirical covariance matrix (Figure 2). The full FIM predicts 340 
considerably more information compared to the simulations (expected D-criterions larger than the 341 
observed values) and predicts total information (D-criterion) that is farther from the empirical values 342 
than the block diagonal calculations. The same trends are evident when looking at SE values for each 343 
parameter (Table 5). We found good agreement between CTS and the block diagonal FIM, while the 344 
full FIM predicted higher precision in numerous parameters than observed.  345 
 346 
  347 
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Discussion 348 
The first statistical developments for the evaluation of the FIM for NLMEM to compare and evaluate 349 
population designs without simulation were performed in the late 90’s. Since then, five different 350 
software tools have been developed. We have compared these tools in terms of design evaluation. 351 
Optimisation was not considered in the present work. It should be noted that most software are 352 
under active development with regular addition of new features.  353 
We compared the expression of the FIM computed by the five different optimal design software 354 
packages for two examples.  The first example was a simple PK model for which the algebraic 355 
solution could be written analytically. When using the same approximation, all optimal design 356 
software packages achieved the same D-efficiency criterion and predicted RSE values (%). The second 357 
example was more complex, had two responses (both PK and PD measurements) and the model was 358 
written as a series of five differential equations. For this example, the D-criterion and RSE 359 
comparisons revealed negligible differences between software. The differences could potentially be 360 
explained by the use of different differential equation solvers, methods of implementing multiple 361 
response calculations, methods for computing numerical derivatives, tolerance levels for ODEs and 362 
numerical implementations of e.g. matrix inverses and solving of linear systems, etc.  These small 363 
differences could be seen even across the MATLAB computations of the FIM. In this work we did not 364 
impose the same implementation of the various steps across software, hence the importance of the 365 
present comparison. 366 
 367 
In both examples the expected SE values from the block diagonal FIM were close to the empirical SE 368 
values obtained from CTS.  The runtimes for all software tools were a few seconds compared to 369 
minutes (warfarin example) or days (HCV example) for the CTS evaluation. Although computational 370 
speed has increased dramatically since the 1990’s, a significant speed advantage is seen with the 371 
developed software tools even without considering design optimisation. For instance for the HCV 372 
PKPD model the CTS took several days for one design, so that optimization of doses and sampling 373 
times would be difficult.  374 
In both examples investigated, the block diagonal FIM calculations give an expected D-criterion that 375 
is very similar to the observed D-criterion based on the inverse of the empirical covariance matrix 376 
and RSE(%) values for parameter match well. In contrast, the full FIM predicts more information 377 
compared to the simulations (expected D-criterions larger than the observed values). More 378 
discussion on the assumptions beyond the block or full matrix can be found in (33) together with 379 
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suggestions of other stochastic approaches. It seems that when using a FO approximation for 380 
computation of the FIM, linearisation around some fixed values for the fixed effects which are then 381 
no longer considered as estimable parameters and therefore corresponds to the block diagonal 382 
matrix, provides the best approach. Also higher order approximations to the FIM are available that 383 
may give better prediction of RSE(%) values (27).  384 
Results using the simple FO approximation and the block diagonal FIM are very close to those 385 
obtained by CTS using both FOCEI and SAEM estimation methods in the two examples. However, 386 
since the expected FIM calculation is computing an asymptotically lower bound of the covariance of 387 
the parameters, and the calculations are based on approximations, the authors suggest that a CTS 388 
study of the proposed final design be performed in order to evaluate the likely performance of the 389 
design in the setting in which it is proposed to be used. Since this would be a single CTS at a specified 390 
design then this should not be computationally onerous compared to attempting to “optimise” 391 
designs using CTS. In addition, using a CTS study of the final design makes it possible to assess the 392 
bias which is not evaluated by the FIM.  393 
In this first comparison between the software, we did only design evaluation for continuous data and 394 
using the simpler FO approximation of the FIM. This first step was necessary before the next work 395 
where we will compare results of design optimisation. Indeed now that we know that similar 396 
criterion across software are obtained, we can compare the rather different optimisation algorithms 397 
implemented. In principle any design variable that is present in the model can be optimised within an 398 
optimal design framework. Examples of design variables that can be optimised are measurement 399 
sampling times, doses, distribution of subjects between elementary designs, number of 400 
measurement samples in an elementary design, etc.  How this is done and which design variables can 401 
be optimised varies between software, but the independent variable (e.g. measurement sampling 402 
times) and the group assignment can be optimised in all software presented in this paper. Results will 403 
depend on the assumptions about the model and the parameter values, so that sensitivity studies 404 
should be performed to implement ‘robust’ designs, i.e. designs that are robust to the assumed a 405 
priori values of the parameters. Approaches for design optimisation using a priori distribution of the 406 
parameters were suggested and implemented for standard nonlinear regression and extended to 407 
population approaches and should also be compared in further studies. 408 
In conclusion, optimal design software tools allow for direct evaluation of population PKPD designs 409 
and are now widely used in industry (25). Choice of software can depend on what platform the user 410 
has available and what features they are looking since the FIM calculation in the different software 411 
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gives similar results. Population approaches are increasingly used and for more complex/ 412 
physiological PD models. It is very difficult to guess, without using one of these tools, what are the 413 
good designs for those complex ODE models and whether the study will be reliable. We suggest that 414 
before performing any population PKPD study, the design should be evaluated with a good balance 415 
between the approach based on the Fisher Matrix (for optimising the design) and CTS (for evaluating 416 
the final design). 417 
 418 
Appendix : Development of the FIM in NLMEM for multiple responses using FO approximation  419 
For each subject i  with design iξ , the elementary Fisher information matrix is defined as 420 
( ) ( )
2 ;
,
i i
i T
L Y
FIM E
ψψ ξ
ψ ψ
 ∂
= −  ∂ ∂ 
       (14) 421 
where ( );i iL Yψ  is the log likelihood of the vector of observations iY  given the population 422 
parameters ψ .  423 
Let ( ) ( )( ), , ,i i i iF F g bθ ξ β ξ= , and ( ) ( )( ), , , , ,i i i i i iH H g bθ ξ ε β ξ ε= , be the vector composed 424 
of the K vectors of nik predicted responses ( )f ,k i ikθ ξ , and error ( ), ,k i ik ikh θ ξ ε  respectively. Then 425 
equation (5) can be written 426 
( ( , ), ) ( ( , ), , )i i i i i iY F g b H g bβ ξ β ξ ε= + .                                                                                (15) 427 
As there is no analytical expression for the log-likelihood ( );i iL Yψ for nonlinear models, a first-order 428 
Taylor expansion around the expectation of ib is used:   429 
( )( )
0
( ( , ), )
, , ( ( ,0), ) i ii i i T
ib
F g bF g b F g b
b
β ξβ ξ β ξ
=
 ∂
≅ +  
 ∂ 
.    (16) 430 
Then equation (16) can be approximated as: 431 
0
( ( , ), )( ( ,0), ) ( ( ,0), , )i ii i i iT
ib
F g bY F g b H g
b
β ξβ ξ β ξ ε
=
 ∂
 ≅ + +
 ∂
 
,   (17) 432 
Therefore, ( )~ N ,i i iY E V  approximately, with marginal expectation iE  and variance iV  given by:  433 
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( ) ( ( ,0), )i i iE Y E F g β ξ≅ =                                                                                     (18) 434 
( ) ( )
0 0
( ( , ), ) ( ( , ), )
,
T
i i i i
i i iT T
i ib b
F g b F g bVar Y V
b b
β ξ β ξ β ξ
= =
   ∂ ∂
≅ = Ω + Σ   
   ∂ ∂   
         (19)  435 
where ( ), iβ ξΣ  is the variance of ( ( ,0), , )i iH g β ξ ε . ( ), iβ ξΣ  has a simple expression for usual 436 
error models where iε  enters linearly, otherwise it can be computed using a first-order linearisation 437 
of H around the expectation of iε .  438 
Then the elementary FIM for the fixed effects using the bock diagonal form (equation 13), has the 439 
following expression: 440 
1( , ) ( , ) ( , )Ti i i iFIM J V Jβ ξ β ξ β ξ−≅        (20) 441 
where 
( ( ,0), )( , ) ii T
F gJ β ξβ ξ β
∂
=
∂
 442 
Of note, when Ω = 0, ( , )iFIM β ξ reduces to the FIM for individual nonlinear regression with 443 
parameters β .  444 
 445 
  446 
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Table 1.  Available features in the software tools available for population design 
evaluation 
 Software 
 PFIM PkStaMp PopDes PopED POPT 
Language 
R Matlab Matlab Matlab 
FreeMat 
Matlab 
FreeMat 
Available on website ✓  ✓ ✓ ✓ 
Library of PKPD models ✓ ✓ ✓ ✓ ✓ 
User defined models ✓ ✓ ✓ ✓ ✓ 
Multi-response models ✓ ✓ ✓ ✓ ✓ 
Designs differ across responses ✓ ✓ ✓ ✓ ✓ 
ODE models ✓ ✓ ✓ ✓ ✓ 
Full FIM ✓ ✓ ✓ ✓  
Full covariance matrix  for  Ω  ✓ ✓ ✓  
Full covariance matrix  for Σ   ✓ ✓  
IOV ✓  ✓ ✓  
Discrete covariates/ power ✓/✓  ✓ / ✓/✓ ✓/ 
FIM: Fisher Information matrix; GUI: Graphical User Interface; IOV: Inter-Occasion Variability; ODE: Ordinary Differential 
Equation; Ω:  interindividual covariance matrix ; Σ: residual covariance matrix ;  
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Table 2 - Model parameters of warfarin PK model 
Parameter Value 
/CL Fβ  (L/h) 0.15 
/V Fβ  (L) 8.00 
kaβ  (1/h) 1.00 
2
/CL Fω   0.07 
2
/V Fω   0.02 
2
kaω   0.60 
2σ  0.01 
CL/F: apparent clearance of the warfarin; V/F: apparent volume of the warfarin; ka: constant of absorption of the warfarin; 
β : fixed effects ; 2ω : interindividual variance;  2σ : residual variance. 
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Table 3 - Model parameters for HCV PK/VK model 
Parameter Value 
p (fixed)
 1
 100 
d (1/d) (fixed)
 1
 0.001 
e (mL/d) (fixed)
 1
 1E-07 
s (mL
-1
/d) (fixed)
 1
 20 000 
kaβ (1/d) 0.80 
keβ (1/d) 0.15 
Vdβ (mL) 100 000 
50EC
β (μg/mL) 0.00012 
nβ  2 
δβ (1/d) 0.20 
cβ (1/d) 7 
2
kaω   0.25 
2
keω  0.25 
2
Vdω  0.25 
50
2
ECω  0.25 
2
nω  0.25 
2
δω  0.25 
2
cω  0.25 
2
PKσ  0.04 
2
PDσ  0.04 
1
 Parameters defined in the section 3.  
ka: rate constant of absorption; ke: rate constant of elimination; Vd: volume of distribution; EC50: drug concentration in the 
blood at which the drug is 50% effective; n: Hill coefficient; δ: rate constant of elimination of infected celss; c: rate constant 
of elimination of viral particles; β : fixed effects; 2ω :  interindividual variance;  2PKσ  : residual variance for the PK 
response; 
2
PDσ : residual variance for the PD response.  
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Table 4 - Fisher Information Matrix (FIM) predicted RSEs (%)  for warfarin PK model with the various software tools compared to empirical 
RSEs (%) 
 
 
 
 
 
 
 
 
 
CL/F: apparent clearance of the warfarin; V/F: apparent volume of the warfarin; ka: constant of absorption of the warfarin; β : fixed effects ; 2ω : interindividual variance;  2σ : residual 
variance. 
 
 
  Block diagonal FIM Full FIM Simulations 
Parameter  PFIM/PkStaMp/PopDes/PopED/POPT PFIM/PkStaMp/PopDes/PopED NONMEM MONOLIX 
kaβ   13.9 4.8 13.6 13.8 
/CL Fβ   4.7 3.6 4.9 4.8 
/V Fβ   2.8 2.6 2.7 2.8 
2
kaω   25.8 26.5 26.6 28.1 
2
/CL Fω   25.6 26.3 26.1 26.6 
2
/V Fω   30.3 30.9 32.4 30.8 
2σ   11.2 12.4 10.9 11.0 
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Table 5 – Fisher Information Matrix (FIM) predicted RSEs (%) for the HCV model parameters with the various software tools compared to empirical 
RSEs 
  Block diagonal FIM Full FIM Simulations 
Parameter  PFIM PkStaMp/PopDes/PopED POPT PFIM PkStaMp/PopDes/PopED MONOLIX 
kaβ   12.0 12.1 13.2 8.6 8.6 12.2 
keβ   10.4 10.5 11.1 6.8 6.9 10.4 
Vdβ   9.9 10.0 11.2 8.3 8.4 9.9 
50EC
β   15.8 15.8 15.7 13.6 13.5 14.5 
nβ   10.5 10.4 10.4 7.4 7.5 10.6 
δβ   9.5 9.4 9.4 8.7 8.5 10.1 
cβ   11.1 11.0 11.0 8.8 8.7 10.3 
2
kaω    39.6 40.0 42.0 42.8 43.2 41.6 
2
keω   30.4 30.8 31.6 36.4 37.2 34.4 
2
Vdω   28.4 28.8 31.6 32.8 33.2 30.4 
50
2
ECω   60.8 60.4 60.0 66.4 66.4 53.2 
2
nω   28.8 28.8 28.8 32.8 32.8 31.6 
2
δω   27.2 27.2 27.2 32.4 31.6 31.6 
2
cω   32.8 32.8 32.4 34.0 33.6 30.0 
2
PKσ   9.0 8.5 8.3 9.3 8.5 10.0 
2
PDσ   8.0 9.0 9.0 8.5 9.3 9.0 
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ka: rate constant of absorption; ke: rate constant of elimination; Vd: volume of distribution; EC50: drug concentration in the 
blood at which the drug is 50% effective; n: Hill coefficient; δ: rate constant of elimination of infected celss; c: rate constant 
of elimination of viral particles; β : fixed effects; 2ω :  interindividual variance;  2PKσ  : residual variance for the PK 
response; 
2
PDσ : residual variance for the PD response. 
  
30 
 
 
 
Figures 
Figure 1. D-criterion predicted by the different software tools for the warfarin PK model compared 
to simulated D-criterion calculated from the inverse of the empirical covariance matrix. 
 
NM FOCEI is calculated from the estimates using the first-order conditional estimation method with interaction in 
NONMEM. The Monolix criterion is calculated from the estimates using the SAEM algorithm in Monolix. 
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Figure 2. D-criterion predicted by the different software tools for the HCV model. Simulated D-
criterion calculated from the inverse of the empirical covariance matrix. 
 
The Monolix criterion is calculated from the estimates using the SAEM algorithm in Monolix. 
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